ArticleInternational journal of cancer2026
Prevalence of Helicobacter pylori Exposure and Risk Factors Among BRCA1 and BRCA2 Carriers.
Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Recent evidence suggests that carriers of a pathogenic germline variant (PGV) in BRCA1 or BRCA2 may have an increased risk of gastric cancer (GC). However, the specific mechanisms underlying gastric carcinogenesis remain uncertain. Strikingly, recent data have demonstrated that Japanese BRCA1 and BRCA2 PGV carriers with Helicobacter pylori (Hp) exposure have a substantially increased risk of GC compared to non-carriers with Hp exposure, indicating that Hp may be an important risk factor for BRCA1 and BRCA2-associated GC. However, rates of Hp exposure amongst broader BRCA1 and BRCA2 PGV cohorts are currently unknown. In this study, 1034 United States-based BRCA1 and BRCA2 PGV carriers along with 293 PALB2, ATM, and TP53 PGV carriers were assessed for Hp exposure by assessing Hp IgG positivity in plasma samples. The combined rate of Hp exposure in BRCA1 and BRCA2 carriers was 17.4%. Individually, BRCA1 and BRCA2 carriers had an exposure rate of 16.4% and 18.2%, respectively. Similarly, PALB2, ATM, and TP53 carriers had a combined Hp exposure rate of 18.4%. Among all groups, non-White race was significantly associated with Hp exposure. Approximately 1 in 6 BRCA1, BRCA2, and other DNA repair-related gene PGV carriers had Hp exposure. Future studies are needed to determine the impact of Hp exposure versus active Hp infection on GC risk in these high-risk individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.